- Home
- EVAX vs CYCN Comparison
EVAX vs CYCN Comparison
Compare EVAX & CYCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVAX
- CYCN
- Stock Information
- Founded
- EVAX 2008
- CYCN 2018
- Country
- EVAX Denmark
- CYCN United States
- Employees
- EVAX N/A
- CYCN N/A
- Industry
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- CYCN Biotechnology: Pharmaceutical Preparations
- Sector
- EVAX Health Care
- CYCN Health Care
- Exchange
- EVAX Nasdaq
- CYCN Nasdaq
- Market Cap
- EVAX 17.8M
- CYCN 8.0M
- IPO Year
- EVAX 2021
- CYCN N/A
- Fundamental
- Price
- EVAX $2.93
- CYCN $2.33
- Analyst Decision
- EVAX Strong Buy
- CYCN
- Analyst Count
- EVAX 2
- CYCN 0
- Target Price
- EVAX $10.00
- CYCN N/A
- AVG Volume (30 Days)
- EVAX 68.5K
- CYCN 24.8K
- Earning Date
- EVAX 10-30-2025
- CYCN 11-13-2025
- Dividend Yield
- EVAX N/A
- CYCN N/A
- EPS Growth
- EVAX N/A
- CYCN N/A
- EPS
- EVAX N/A
- CYCN N/A
- Revenue
- EVAX $3,176,000.00
- CYCN $2,174,000.00
- Revenue This Year
- EVAX N/A
- CYCN N/A
- Revenue Next Year
- EVAX $425.50
- CYCN N/A
- P/E Ratio
- EVAX N/A
- CYCN N/A
- Revenue Growth
- EVAX 1042.45
- CYCN N/A
- 52 Week Low
- EVAX $1.20
- CYCN $1.27
- 52 Week High
- EVAX $16.69
- CYCN $9.47
- Technical
- Relative Strength Index (RSI)
- EVAX 51.89
- CYCN 45.15
- Support Level
- EVAX $2.81
- CYCN $2.13
- Resistance Level
- EVAX $3.04
- CYCN $2.59
- Average True Range (ATR)
- EVAX 0.21
- CYCN 0.21
- MACD
- EVAX -0.00
- CYCN 0.01
- Stochastic Oscillator
- EVAX 68.64
- CYCN 32.79
About EVAX Evaxion Biotech
Evaxion AS is a techBio company based on its AI platform, AI-Immunology. Evaxion's proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing innovative and targeted treatment options.
About CYCN Cyclerion Therapeutics Inc.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.